Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of COVID-19 pandemic on viral keratitis.

Bioinformation·2026
Same author

Retinopathy of prematurity: Clinical profiles and risk factors.

Bioinformation·2026
Same author

Ocularultrasound versus SD-OCT in early papilledema differentiation.

Bioinformation·2026
Same author

Tuneable Permeability of Cellulose Nanofibrils-based Membranes in Next-Generation Barrier-On-Chip Systems.

Chembiochem : a European journal of chemical biology·2026
Same author

An insight into the jarosite waste-driven phytotoxicity in Salvia hispanica L.

Environmental science and pollution research international·2026
Same author

A comparative evaluation of peri-implant soft and hard tissues between internal hexagonal and internal conical type of implant-abutment connection: A randomized controlled trial.

Journal of Indian Prosthodontic Society·2026

Related Experiment Video

Updated: Jun 3, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940:

Richard P Baum1, Tianzhi Zhao2,3,4,5, Vivianne Jakobsson2,3,4,5

  • 1Curanosticum Wiesbaden-Frankfurt, Department of Molecular Radiotherapy, ICPO Center of Excellence, DKD HELIOS Klinik, Wiesbaden, Germany; j.zhang@nus.edu.sg baumrp@gmail.com.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|June 1, 2026
PubMed
Summary
This summary is machine-generated.

First-in-human results show that fibroblast activation protein (FAP)-targeted radiopharmaceutical therapy (FRT) using 3BP-3940 is feasible and well-tolerated in end-stage cancer patients. This targeted therapy demonstrated significant tumor uptake and promising survival benefits.

Keywords:
21 advanced malignancies3BP-3940FAP-targeted radiopharmaceutical therapy[177Lu]Lu-[90Y]Y-adenocarcinomaand [225Ac]Ac-3BP-3940fibroblast activation protein

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Fibroblast activation protein (FAP) is specifically expressed in tumors, making it a target for precision imaging and therapy.
  • FAP-targeted radiopharmaceutical therapy (FRT) offers a novel approach for treating various advanced cancers.

Purpose of the Study:

  • To evaluate the safety, efficacy, and biodistribution of the FAP-targeted cyclic peptide 3BP-3940 labeled with 177Lu, 90Y, and 225Ac in patients with end-stage cancer.
  • To assess treatment response and survival outcomes following FRT.

Main Methods:

  • Eighty-eight patients with 21 types of advanced metastatic solid tumors received 227 cycles of 177Lu-, 90Y-, or 225Ac-labeled 3BP-3940 FRT.
  • Tumor uptake was confirmed by [68Ga]Ga-3BP-3940 PET/CT prior to treatment.
  • Toxicity, treatment response, and survival were assessed using standardized criteria and Kaplan-Meier analysis.

Main Results:

  • FRT with 3BP-3940 was well-tolerated, with most adverse events being mild (e.g., pain, nausea, fatigue).
  • Objective response rate was 66.7% (3.9% complete remission, 62.7% partial remission), and disease control rate was 80.4%.
  • Median overall survival was 7.0 months from FRT initiation, with promising survival benefit observed.

Conclusions:

  • 3BP-3940 FRT is a feasible and safe treatment option for patients with end-stage cancer, utilizing 177Lu, 90Y, or 225Ac.
  • The therapy demonstrated favorable biodistribution, significant tumor uptake, and long retention with high tumor-to-background ratios.
  • Further randomized trials are warranted to confirm these promising findings in a larger patient cohort.